SCHEMBL4670604

SCHEMBL4670604

O=C(O)C(O)=CC(=O)c1[nH]ncc1S(=O)(=O)c1ccc(F)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 3/20 0.39
HTR2A P28223 5/20 0.37
KCNH2 Q12809 3/20 0.37
MMP1 P03956 1/20 0.37
MMP2 P08253 1/20 0.37
MMP3 P08254 1/20 0.37
MMP9 P14780 1/20 0.37
MMP12 P39900 1/20 0.37
MMP13 P45452 1/20 0.37
MMP14 P50281 1/20 0.37
IKBKB O14920 1/20 0.37
AKR1B1 P15121 1/20 0.36
PTGS2 P35354 1/20 0.35
AKR1C2 P52895 1/20 0.35
AKR1C1 Q04828 1/20 0.35
AKR1C3 P42330 1/20 0.35
CCNA2 P20248 2/20 0.34
CYP2D6 P10635 1/20 0.34
HTR2C P28335 1/20 0.34
CCNA1 P78396 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4674415 0.88 HTR6 (0.38) CDK2AKR1B1NPSR1
SCHEMBL4673939 0.87 ALDH1A1 (0.38) AKR1B1AKR1C2AKR1C1AKR1C3
SCHEMBL4676852 0.81 MMP1 (0.38) HTR2AKCNH2MMP1MMP2MMP3
SCHEMBL4676854 0.81 MMP1 (0.38) HTR2AKCNH2MMP1MMP2MMP3
SCHEMBL4675183 0.80 HTR2A (0.35) CDK2HTR2AKCNH2MMP1MMP2
SCHEMBL4673902 0.79 CDK2 (0.33) CDK2HTR2AKCNH2MMP1MMP2
SCHEMBL4672206 0.76 MMP1 (0.39) HTR2AKCNH2MMP1MMP2MMP3
SCHEMBL4672202 0.76 MMP1 (0.39) HTR2AKCNH2MMP1MMP2MMP3
SCHEMBL4677419 0.73 AKR1B1 (0.47) HTR2AKCNH2AKR1B1PTGS2AKR1C2
SCHEMBL4674291 0.73 MEN1 (0.40) CDK2HTR2ACCNA2HTR2CCCNA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 CDK2 363/4885HTR2A 441/4885KCNH2 3174/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.